tors were issued between 1983 and 1986 for collecting necessary data in order to work out the amount recoverable under the said provisions of DPCO, 1979.

(d) and (e) The details of tentative amounts worked out in respect of drugs mentioned in part (a) are given in the enclosed Statement (*See* below)

(f) The amounts from other formulators would be recovered as per due process of law.

Statement

(Rs. in lakhs)

Gentamycin	Tentative amount assessed
(1) M/s. Fulford (I) Ltd.	194.52
(2) M/s. Biochem Pharma Ltd.	33.88
(3) M/s. Lyka Labs. Ltd	17.47
(4) M/s. Nicholas Labs. Ltd	53.03
Metronidazole	
(1) M/s. Boots Company Ltd	42.82
(2) M/s. Smith Stanistreet Pharmaceuticals Ltd.	7.02
(3) M/s. K.S.D.P.L.	5.50
(4) M/s. Khandelwal Labs.	1.34
(5) M/s. IDPL	20.33

Unintended Benefit on Pyrimon

2428. SHRI SANTOSH KUMAR SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what was the price of Pyrimon fixed under DPCO, 1987 and when it was fixed;

(b) what was the price fixed under DPCO, 1979 and what was the price at which this product was sold;

(c) what is the present price at which this durg is being sold;

(d) whether it is a fact that this product has been selling at a higher price than that approved; and

(e) what steps have been taken to stop overcharging and recover the unintended benefit?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (e) The required information to the extent

available will be collected and laid on the Table of the House.

Prices of Proxyvon range formulations

2429. SHRI BHAGATRAM MANHAR:
DR. G. VIJAYA MOHAN REDDY:

Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question No. 4 given in the Rajya Sabha on the 24th April, 1989 and state:

(a) on which date and at which price the combination of Dextropropoxyphene with Ibuprofen was introduced by the company;

(b) what price was fixed of this combination under DPCO, 1979 and what was the price charged for this product;

(c) what were the prices of proxyvon range of formulations charged by the company for each pack from 5th March, 1986 to 1st April, 1989;

(d) whether it is a fact that prices of Proxyvon range formulations have been fixed very often;

(e) if so, how many times the prices of the drug were fixed before 5th March, 1986 and what was the price each time of each pack;

(f) whether his Ministry served show cause notices to the company in 1984 and 1985; and

(g) if so, what are the details thereof and what action has been taken thereon?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (g) The required details to the extent available would be collected and laid on the Table of the Rajya Sabha.

Revision of drug prices

2430. SHRI ASHOK NATH VERMA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has revised the prices of drugs which were under litigation in Supreme Court from retrospective effect;

(b) if so, what are the names of those drugs and dates from which each revised price is applicable;

(c) whether it is also fact that neither the Department of Legal Affairs nor the Supreme Court agreed to concede to this type of request from the producers;

(d) if so, on what basis such a decision has been taken by his Ministry and who gave such approval; and

(e) what corrective steps are being taken in the matter?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (e) Since the prices of drugs involved in the Supreme Court cases had not been revised for a long time, a decision was taken at the appropriate level to give a hearing to the companies concerned on their price revision application for prices after December, 1983. Accordingly the companies are heard by a Price Revision Committee.

Price control on Drugs having large sales turnover

2431. SHRI B. SATYANARAYAN REDDY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the medicines Largeotil, Mellaril, Siquil